吉西他滨（Gemcitabine）联合铂类药物治疗老年中晚期非小细胞肺癌（NSCLC）的临床观察

目的：探讨吉西他滨(Gemcitabine)联合铂类药物治疗老年中晚期非小细胞肺癌(NS(NSCLC)的临床疗效和毒性。方法：予吉西他滨(Gemcitabine)1000mg/m^2第1、8天静滴并联合铂类药物治疗老年非小细胞肺癌(NSCLC)20例，三周为一治疗周期，两周期后评价疗效和毒副作用，随访缓解期和生存期。结果：本组20例病例中，治疗总有效40％，中位缓解期7个月，中位生存期9个月，主要毒副作用为骨髓抑制和胃肠道反应。其中白细胞减少发生率为80％，血小板减少发生率为60％。结论：吉两他滨(Gemcitabine)对老年非小细胞肺癌(NSCLC)有较好疗效，主要毒性反应为较严重的血液学毒性，老年患者最好辅以G-CSF或GM—CSF以及免疫与营养支持治疗，则能顺利完成化疗，吉西他滨(Gemcitabine)联合铂类药物可做为老年非小细胞肺癌(NSCLC)的一线治疗方案。

A Clinical Research on of Gemcitabine and Platinum Medicines in the Treatmentof Elderly Patients with Middle-advanced Non-small Cell Lung Cancer

Objective:To investigate the efficacy and toxicity of Gemcitabine and Platinum Medicines in the treatment of elderly patients with middle-advanced non-small cell lung cancer.Methods:Twenty elderly patients with middle-advanced non-small cell lung cancer were treated by combination chemotherapy of Gemcitabine and Platinum Medicines for two cycles:Gemcitabine 1000mg/m 2 IV on day 1?8,every three weeks as one cycle.The response,toxicity,telievable period and survival period were evaluated.Results:The total response rate was 40%,the median relievable period was 7 months,the median duration of survival was nine months,and the major toxicity was inhibition of bone marrow and digestive reaction.The rate of decrease in leukocyte and platelet separately was 80% and 60%.Conclusion:Combination chemotherapy of Gemcitabine and Platinum medicines is effective in the treatment of elderly patients with middle-advanced non-small cell lung cancer.The main adverse effects are severe hematological toxicities.Combination chemotherapy will be completed successfully when G-CSF or GM-CSF,and immunity and nutrition used as a support treatment.Gemcitabine and Platinum can be used as first-line protocol chemotherapy in non-small cell lung cancer.